This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Posaconazole parenteral

Updated 2 Feb 2023 | Triazole antifungals


Parenteral formulations containing posaconazole

Drugs List

  • NOXAFIL 300mg/16.7ml concentrate for solution for infusion
  • posaconazole 300mg/16.7ml concentrate for solution for infusion
  • Therapeutic Indications


    Prophylaxis of fungal infection in haematopoietic stem cell transplant pts
    Prophylaxis of invasive fungal infection in patients receiving chemotherapy
    Treatment of aspergillosis when other treatment unsuitable/ineffective
    Treatment of chromoblastomycosis when itraconazole unsuitable/ineffective
    Treatment of coccidioidomycosis when other treatment unsuitable/ineffective
    Treatment of fusariosis when amphotericin unsuitable/ineffective
    Treatment of mycetoma when itraconazole unsuitable/ineffective

    Treatment of the following invasive fungal infections in adults:
    Invasive aspergillosis in patients who are unresponsive or intolerant to amphotericin B or itraconazole.
    Fusariosis in patients who are unresponsive or intolerant to amphotericin B.
    Chromoblastomycosis and mycetoma in patients who are unresponsive or intolerant to itraconazole.
    Coccidioidomycosis in patients who are unresponsive or intolerant to amphotericin B, itraconazole or fluconazole.

    'Unresponsive' is defined as the progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.

    Prophylaxis of invasive fungal infections in the following patients:
    Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia or myelodysplastic syndrome expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections.
    Haematopoietic stem cell transplant recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.


    Posaconazole is also available in oral formulations. The manufacturer suggests switching to an oral formulation as soon as patient condition allows. Consult product information for oral posaconazole if switching.


    Treatment of invasive fungal infections when other treatment unsuitable or ineffective
    300 mg twice a day on first day, then 300 mg once a day thereafter.

    Duration of therapy should be based on the severity of the infection, the recovery from immunosuppression, and the clinical response to therapy.

    Prophylaxis of invasive fungal infections
    300 mg twice a day on first day, then 300 mg once a day thereafter.

    For patients with acute myelogenous leukaemia or myelodysplastic syndromes, prophylaxis with posaconazole should begin several days before the anticipated onset of neutropenia and continue for 7 days after the neutrophil count rises above 500 cells per cubic millimetre.


    (See Dosage; Adult).

    Patients with Renal Impairment

    Creatinine clearance below 50 ml/minute
    Accumulation of the intravenous vehicle, Betadex Sulfobutyl Ether Sodium (SBECD), is expected to occur. The manufacturer suggests switching to oral formulations containing posaconazole in these patients unless the benefit outweighs the risk of using parenteral forms. If used serum creatinine levels should be closely monitored.


    Administer via a central venous line (including a central venous catheter) or peripherally inserted central catheter (PICC) by slow intravenous infusion over approximately 90 minutes.

    If a central venous catheter is not available, a single infusion may be administered through a peripheral venous catheter over approximately 30 minutes to reduce likelihood of infusion site reactions.


    Children under 18 years
    Acute porphyria

    Precautions and Warnings

    Family history of long QT syndrome
    Restricted sodium intake
    Cardiac arrhythmias
    Cardiac failure
    Hepatic impairment
    History of torsade de pointes
    Long QT syndrome
    Renal impairment - creatinine clearance below 50ml/minute
    Sinus bradycardia

    Correct electrolyte disorders before treatment
    Sodium content of formulation may be significant
    Advise ability to drive/operate machinery may be affected by side effects
    Treatment to be initiated and supervised by a specialist
    Dilute and use as an infusion
    Perform ECG before treatment
    If hepatic impairment symptoms occur monitor LFT & consider discontinuation
    Monitor ECG in patients at risk of QT prolongation
    Monitor electrolytes, esp potassium, magnesium and calcium during therapy
    Monitor hepatic function
    Monitor patients at risk for signs & symptoms of thromboembolism
    Monitor serum creatinine in patients with renal impairment
    Female: Ensure adequate contraception during treatment

    Pregnancy and Lactation


    Use posaconazole with caution during pregnancy.

    Briggs suggests, due to the limited human data, posaconazole should be avoided during pregnancy, especially during the first trimester. If the condition requires posaconazole and the benefit is considered to outweigh the potential risk, posaconazole may be given at the lowest possible dose. The manufacturer suggests there are insufficient data on the use of posaconazole in pregnant women. Posaconazole must not be used during pregnancy unless the benefit to the mother clearly outweighs the potential risk to the foetus.

    Due to the molecular weight (about 701), low metabolism and long half-life of posaconazole, it is considered likely that posaconazole will cross the placenta to the foetus.

    Animal studies have shown reproductive toxicity, but due to the absence of human clinical experience the risk of toxicity during human pregnancy is unknown.

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    Posaconazole is contraindicated in breastfeeding.

    Briggs suggests the effect of potential exposure to the infant via breast milk is unknown but severe treatment toxicity has been reported in adults. The manufacturer suggests breastfeeding must be stopped on initiation of treatment with posaconazole.

    At the time of writing, there are no data on the use of posaconazole during human breastfeeding. Animal studies have shown that posaconazole is excreted in rat milk.

    Due to its low molecular weight (about 701), low metabolism (about 17%) and long half-life (range 20 to 66 hours), it is considered likely that posaconazole will be excreted in human breast milk. The effects of posaconazole on a nursing infant are unknown.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at

    Side Effects

    Acute adrenal insufficiency
    Allergic reaction
    Altered liver function tests
    Blood dyscrasias
    Blurred vision
    Cardiac arrest
    Cardiac failure
    Cerebrovascular accident
    Chest discomfort
    Coagulation disorders
    Decreased appetite
    Decreased gonadotrophins
    Deep vein thrombosis (DVT)
    Dream abnormalities
    Dry mouth
    ECG changes
    Electrolyte disturbances
    Gastroesophageal reflux disease
    GI disorders
    Haemolytic uraemic syndrome
    Hearing disturbances
    Hepatic impairment
    Hypersensitivity reactions
    Infusion-related symptoms
    Interstitial pneumonitis
    Menstrual disturbances
    Mucosal inflammation
    Myocardial infarction
    Nasal congestion
    Peripheral neuropathy
    Prolongation of QT interval
    Psychotic disorder
    Pulmonary embolism
    Pulmonary hypertension
    Rectal discomfort
    Reduced visual acuity
    Renal failure
    Renal impairment
    Respiratory arrest
    Skin disorder
    Sleep disturbances
    Splenic infarction
    Sudden death reported
    Thrombotic thrombocytopenic purpura
    Torsades de pointes
    Ventricular tachycardia


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: November 2014

    Reference Sources

    Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 9th edition (2011) ed. Briggs, G., Freeman, R. and Yaffe, S. Lippincott Williams & Wilkins, Philadelphia.

    Joint Formulary Committee. British National Formulary(online) London: BMJ Group and Pharmaceutical Press. Accessed on 20 November 2014.

    Summary of Product Characteristics: Noxafil 300 mg concentrate for solution for infusion. Merck Sharp and Dohme. Revised September 2014.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.